Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 27, 2019
Daily News
November 27, 2019
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- “All-Generation” Panel Cites Coverage of OTC-Like Drugs as Policy Issue
November 27, 2019
- Japan’s First Biosimilars for Nesp, Forteo Hit Shelves
November 27, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Hisamitsu’s Osteoarthritis Patch Drug Delivers Positive PII Data; PIII Launch Planned in FY2020
November 27, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- Astellas Pharma Grabs China Approval for Xtandi
November 27, 2019
- Kyowa Kirin, Ardelyx Bolster Partnership with Additional Research Deal, US$20 Million Equity Investment
November 27, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…